Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares in the company, valued at $19,839,052.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Neurocrine Biosciences, Inc. (NBIX) traded down $1.00 on Tuesday, reaching $70.98. The company’s stock had a trading volume of 603,938 shares, compared to its average volume of 1,106,568. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same period last year, the firm posted ($0.43) earnings per share. equities analysts predict that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.
Several brokerages recently commented on NBIX. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, November 14th. Robert W. Baird reiterated a “buy” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Barclays upped their target price on Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. Finally, Deutsche Bank reiterated a “buy” rating and issued a $79.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $78.88.
COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Director Sells $729,200.00 in Stock” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/05/neurocrine-biosciences-inc-nbix-director-sells-729200-00-in-stock.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
What are top analysts saying about Neurocrine Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neurocrine Biosciences Inc. and related companies.